The counter regulatory response induced by CpG oligonucleotides prevents bleomycin induced pneumopathy by unknown
Kinjo et al. Respiratory Research 2012, 13:47
http://respiratory-research.com/content/13/1/47RESEARCH Open AccessThe counter regulatory response induced by CpG
oligonucleotides prevents bleomycin induced
pneumopathy
Takeshi Kinjo1, Koji Tomaru1, Diana C Haines2 and Dennis M Klinman1*Abstract
Bleomycin (BLM) induces life-threatening pneumonitis and pulmonary fibrosis in 20% of patients, limiting its use as
a chemotherapeutic agent. Oligonucleotides expressing immunostimulatory CpG motifs (CpG ODN) stimulate cells
that express Toll-like receptor 9 to initiate an inflammatory response. This short-lived inflammation is physiologically
suppressed by a counter-regulatory process that peaks five days later. Using a murine model of BLM-induced lung
injury, the effect of CpG ODN treatment on pulmonary inflammation, fibrosis and mortality was examined.
Administering CpG ODN 5 days before BLM (so that the peak of the counter-regulatory process induced by CpG
ODN coincided with BLM delivery) resulted in a dose-dependent reduction in pulmonary toxicity (p< 0.005).
Delaying the initiation of therapy until the day of or after BLM administration worsened the inflammatory process,
consistent with the counter-regulatory process rather than initial pro-inflammatory response being critical to CpG
induced protection. The protection afforded by CpG ODN correlated with reduced leukocyte accumulation and
inflammatory cytokine/chemokine production in the lungs. These changes were associated with the increased
production of IL-10, a critical element of the counter-regulatory process triggered by CpG ODN, and the
concomitant down-regulation of BLM-induced IL-17A and TGF-β1 (which promote pulmonary toxicity). This work
represents the first example of the physiologic counter-regulation of TLR induced immune activation being
harnessed to block an unrelated inflammatory response.
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Bleomycin is effective in the chemotherapy of various
cancers including squamous cell carcinomas of the head
and neck, cervix, and esophagus, germ cell tumors and
both Hodgkins and non-Hodgkins lymphoma [1-3].
BLM exerts its anti-tumor activity by generating oxygen
and free radicals via the reduction of Fe (II) to Fe (III).
These free radicals cause DNA strand breakage and cell
death [4-6]. BLM is metabolized/inactivated under
physiologic conditions by bleomycin hydrolase. As there
is a paucity of this enzyme in the lungs, they are un-
usually susceptible to BLM-induced toxicity. While
several pulmonary syndromes associated with BLM
administration have been described, the most common* Correspondence: klinmand@mail.nih.gov
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reproduction in any medium, provided the ordose-limiting side effect of this therapy is interstitial
pneumonitis progressing to fibrosis [7-9]. Approximately
20% of patients treated with BLM develop pneumonitis,
with a mortality that approaches 20% [7,10-12].
The lung cells damaged by BLM release uric acid and
other factors that trigger alveolar macrophages to secrete
pro-inflammatory cytokines and chemokines (including
IL-1β, IL-6, KC and MIP-2). These recruit additional in-
flammatory cells to the lung that contribute to the devel-
opment of bleomycin-induced pneumonitis (BIP) and
pulmonary fibrosis [13-15]. Recent studies indicate that
IL-17A, TGF-β, and IL-10 are critical regulators of
BLM-induced pneumopathy. IL-17A and TGF-β
synergistically promote the development of BIP whereas
IL-10 down-regulates IL-17A and thus abrogates disease
[16]. The importance of these factors was confirmed in
animal models showing that BLM-induced lung injury
was reduced in mice in which IL-17A or its receptord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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more severe BLM-induced lung inflammation and
fibrosis [16-19].
The unmethylated CpG motifs present in bacterial
DNA stimulate cells that express Toll-like receptor 9
(TLR9). This interaction triggers a short-lived innate
immune response characterized by the production of
pro-inflammatory cytokines and chemokines [20-22].
The immune stimulation induced by bacterial DNA is
duplicated by synthetic oligonucleotides expressing CpG
motifs (CpG ODN).
Microarray identification of the genes triggered by CpG
ODN showed that the inflammatory response peaked on
day 1, but that >96% of these genes were suppressed by a
counter-regulatory process that peaked on day 5 [23,24].
IL-10 was identified as a key mediator of this down-
regulatory process, based on both bioinformatic and func-
tional studies of CpG-induced inflammation [23,25,26]. As
noted above, IL-10 also reduces BLM-induced pulmonary
inflammation by down-regulating IL-17A production. This
combination of findings raised the possibility that the
counter-regulatory process induced by CpG ODN might
be harnessed to limit BLM-dependent pneumonitis. A
murine model was used to examine the effect of CpG
ODN on BLM-induced morbidity and mortality, and
analyze the impact of this treatment on the production and
regulation of pro-inflammatory cytokines and chemokines.Materials and methods
Oligodeoxynucleotides
Phosphorothioate CpG ODN 1555 (sequence: GCTA
GACGTTAGCGT) and control ODN 1612 (sequence:
GCTAGAGCTTAGGCT) were synthesized at the Cen-
ter for Biologics Core Facility. ODNs were administered
by intraperitoneal injection in all experiments. All ODNs
were free of endotoxin and protein contamination.BLM-induced lung injury model
Female C57BL/6 mice were studied at 7-12 wk of age.
BLM (Sigma-Aldrich, St. Louis, MO) in 50 μl of PBS was
instilled endotracheally into the lungs of anesthetized mice
using a 24-gauge catheter. All experiments were approved
by the NCI Animal Care and Use Committee, and mice
were monitored daily.Collection of bronchoalveolar lavage (BAL) fluid and cells
The trachea was cannulated with a 22-gauge catheter and
BAL fluid collected as previously described [27]. BAL was
centrifuged and supernatants analyzed as described below.
Cell pellets were re-suspended and analyzed histologically
after cytocentrifugation and Diff-Quick staining (Dade
Behring, Deerfield, IL).In vitro stimulation of LN and BAL cells
A single cell suspension prepared from the draining
thoracic LN and BAL was plated at 0.5 - 4 x 105 cells
per well in 96-well microtiter plates and stimulated with
50 ng/ml PMA and 1 μg/ml Ionomycin (Sigma-Aldrich)
for 4 hr in RPMI 1640 medium supplemented with 5%
FCS, 50 U/ml penicillin and 50 μg/ml streptomycin.
Elisa
KC, MIP-2, IL-1β, IL-6 and IL-17A levels in BAL and
culture supernatants were measured by ELISA, as previ-
ously described [28]. TGF-β1 was measured by ELISA
(R&D Systems).
Evaluation of lung fibrosis
Total soluble lung collagen was detected using the Sircol
collagen assay (Biocolor, Northern Ireland, UK). Lung
tissue was fixed and stained with Masson’s Trichrome.
The severity of lung fibrosis were evaluated by a path-
ologist blinded to the origin of each sample.
RNA isolation and quantitative RT-PCR
RNA was extracted from homogenized lung using the
RNeasy Mini Kit (QIAGEN, Valencia, CA) and cDNA was
generated using the Reverse Transcription Kit (QIAGEN).
The cDNA from each sample was used for a quantitative
RT-PCR based on TaqMan chemistry using the Step One
Plus real-time PCR System (Applied Biosystems). The
reaction mixture contained Taqman Gene Expression
Master Mix with Taqman probes for the IL-10 gene with
FAM dye (Mm00439616m1) and for the GAPDH gene
with VIC dye (Applied Biosystems, Foster City, CA).
Statistical analysis
Differences between groups were assessed using a one-way
ANOVA and differences in survival rate were determined
using the Kaplan-Meier log-rank test. P values≤ 0.05 were
considered significant for all analyses.
Results
Mice pre-treated with CpG ODN survive BLM-induced
lung injury
Preliminary studies established that intra-tracheal instilla-
tion of 0.05 U of BLM consistently induced severe
pulmonary inflammation. The severity of the resultant
pneumonitis required that 80% of the animals be eutha-
nized within 3 wk. As CpG ODN treatment induces a
short-term inflammatory response that is down-regulated
under physiological conditions after 3 - 5 days, the effect of
CpG ODN administration on BLM induced toxicity was
evaluated. As seen in Figure 1A, lethal pulmonary inflam-
mation was prevented by treating mice with 200 μg of CpG
ODN 5 days before BLM instillation (p< 0.005). This effect
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Days after BLM instillation
Figure 1 CpG ODN protect mice from lethal BLM-induced lung
injury. 0.05 U of BLM was delivered into the lungs of C57BL/6 mice
via the intra-tracheal route on day 0. A) Five days earlier, mice were
injected i.p. with 200 μg of control or CpG ODN. B) Mice were
treated with 0 - 200 μg of CpG ODN 5 days before BLM. C) Mice
were treated with 200 μg of CpG ODN 5 days before, at the same
time, or 5 days after BLM instillation. Data represent combined
results from 2-3 independent experiments involving a total of 11-20
mice/group. Survival was analyzed with Kaplan-Meier statistics using
















































































































Figure 2 Effect of CpG ODN on BLM-induced cytokine
production. Mice were injected i.p. with 200 μg of control or CpG
ODN 5 days before 0.05 U of BLM was delivery intra-tracheally. The
concentration of KC, MIP-2, IL-6 and IL-1β in BAL fluid collected 1
(KC and MIP-2) or 3 (IL-6 and IL-1β) days after BLM instillation was
determined by ELISA. Results represent the average fold change+ SE
in cytokine levels compared to BLM alone in 2-3 independent
experiments involving a total of 10-19 mice/group. **; p< 0.005.
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dependent, with only 60% and 30% of mice surviving when
treated with 50 μg and 10 μg of CpG ODN, respectively
(Figure 1B). The timing of ODN delivery had a major im-
pact on survival. Whereas CpG ODN administered 5 days
before BLM challenge was highly protective, delaying treat-
ment until the day of or five days after BLM instillation
conferred no significant protection (Figure 1C). Adminis-
tering CpG ODN 3 days before BLM instillation (when the
counter-regulatory process was nascent) was less effective,
leading to a 26% improvement in survival (p< 0.05, data
not shown).
Pre-treatment with CpG ODN reduces BLM-induced
pulmonary inflammation
Previous studies showed that uric acid released by BLM-
damaged lung cells trigger alveolar macrophages via the
Nalp3 inflammasome signaling cascade [14]. These macro-
phages produce chemokines (including KC, MIP-2) and
pro-inflammatory cytokines (including IL-6 and IL-1β) that
recruit other inflammatory cells to the lung, culminating in
pulmonary fibrosis [13-15].To evaluate the effect of CpG treatment on BLM-
induced lung injury, BAL fluid was collected 1 - 7 days
after BLM instillation. Consistent with previous reports,
BLM triggered a significant increase in the concentra-
tion of KC and MIP-2 (peaking on day 1 and persisting
through day 5) as well as IL-6 and IL-1β (peaking day 3
and persisting though day 7, Figure 2 and data not
shown). Consistent with the improved survival of mice
pre-treated with CpG ODN, the BAL of CpG treated
mice had significantly lower levels of these factors than
did untreated animals (p< 0.005, Figure 2). The accu-
mulation of infiltrating leukocytes (most notably
neutrophils) in the BAL of CpG treated mice was also
significantly reduced (p< 0.005; Figure 3). By compari-
son, control ODN had no significant effect on leukocyte
infiltration or pulmonary cytokine/chemokine levels
after BLM administration.
Pre-treatment with CpG ODN inhibits lung fibrosis
BLM causes acute lung injury that evolves into chronic
pulmonary fibrosis [7-9]. The accumulation of collagen
in the lung is a characteristic marker of the magnitude
of this effect. To examine whether CpG ODN impacts
chronic pulmonary fibrosis, a sub-lethal dose of BLM












































































(A)                           (B)
Figure 3 Effect of CpG ODN on BLM-induced leukocyte accumulation in the lungs. Mice were injected i.p. with 200 μg of control or CpG
ODN 5 days before 0.05 U of BLM was delivery intra-tracheally. A) The number of leukocytes present in BAL collected 1 - 7 days after BLM instillation
was determined. Statistic significance was analyzed by longitudinal regression analysis. B) Cell differentials (based on 300 leukocytes/sample) in BAL
collected 5 days after BLM instillation were performed on cytocentrifuge preparations after Diff-Quick staining. Data show the mean ± SE of the
combined results from 2 independent experiments involving 10 mice/group/time point. **; p< 0.005.
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BLM alone induced a 100% increase in lung collagen
levels within 2 wk of administration. This effect was sig-
nificantly reduced by pre-treatment with CpG ODN
(Figure 4A). No reduction in fibrosis was observed in
animals treated with control ODN.
Histologic analysis of lung tissue from these animals
confirmed that BLM caused the development of patchy,
multi-focal inflammation and markedly increased colla-
gen deposition (Figure 4B). These histologic changes
were unaffected by the administration of control ODN
or PBS, whereas CpG ODN treatment resulted in signifi-
cantly less severe inflammatory changes and lower levels
of collagen deposition (Figure 4B, C).
Effect of CpG ODN on IL-10, IL-17 and TGF-β expression
Recent reports show that IL-17A plays a critical role in
BLM-induced lung injury, and that it interacts synergistic-
ally with TGF-β to amplify the development of fibrosis
[16-18]. The effect of CpG ODN on IL-17A and TGF-β1
levels was therefore examined. As expected, the concen-
tration of both factors rose significantly in the BAL of
mice receiving BLM (Figure 5 and data not shown). Pre-
treatment with CpG (but not control) ODN significantly
reduced the concentration of both cytokines (Figure 5).
This effect was attributable to a decrease in the produc-
tion (rather than accelerated catabolism) of these factors,
as lymphocytes isolated from the draining LN and BAL of
CpG treated animals produced significantly less IL-17Awhen re-stimulated with PMA and ionomycin in vitro
(Figure 5A).
Recent evidence suggests that IL-10 can reduce BLM-
induced lung injury by inhibiting the production of IL-17A
and TGF-β [16]. Moreover, previous studies showed that
IL-10 was an important element of the counter-regulatory
process induced by CpG ODN [24]. Thus, the effect of
CpG treatment on pulmonary IL-10 mRNA expression was
examined. Extending early findings that examined IL-10
gene expression in the spleen, mice treated with CpG ODN
showed slightly increased levels of IL-10 in the lungs 5 days
later. When these animals were treated with BLM, IL-10
mRNA levels were significantly higher in the CpG treated
vs control groups 3 days later (Figure 6).
Further studies examined whether IL-10 alone
accounted for the reduced inflammation observed after
CpG was administered to BLM treated mice. Initial
efforts to utilize IL-10 KO mice failed, as that strain be-
came acutely ill after CpG administration (independent
of BLM treatment). Thus, normal mice were injected
with neutralizing doses of anti-IL-10 receptor antibodies
(anti-IL-10R Abs) immediately prior to and 5 days after
BLM administration. Unfortunately, no reduction in
CpG dependent protection was observed in those studies
(Figure 7).
Discussion
CpG ODN activate the innate immune system by stimu-



































































Figure 4 Pretreatment with CpG ODN inhibits lung fibrosis. Mice were injected i.p. with 200 μg of control or CpG ODN 5 days before 0.03 U
of BLM or PBS (no BLM) was delivery intra-tracheally. Lungs were removed 14 days later. A) The amount of collagen was determined analytically
using the Sircol collagen assay. Data show the percent change in the amount of collagen in experimental groups vs mice that did not receive
BLM. This was calculated by combining results from 3 independent experiments involving 10-15 mice/group. B) Representative histologic sections
from these lungs. C) Lung tissue was fixed and stained with Masson’s Trichrome. The severity of lung fibrosis were graded as (0) none, (1)
minimal, (2) mild, (3) moderate and (4) severe. Data shows the mean + SE of the combined results from 2 independent experiments involving 6-7






























































































Figure 5 CpG ODN treatment decreases IL-17A and TGF-β1 production. Mice were treated as described in Figure 2. A) Cells were isolated
from the BAL and draining thoracic lymph nodes 3 days after BLM instillation. These cells were stimulated in vitro with 50 ng/ml PMA plus 1 μg/ml
ionomycin for 4 hours. The concentration of IL-17A in culture supernatants was determined by ELISA. B) The concentration of TGF-β1 in BAL fluid
collected 3 days after BLM instillation was determined by ELISA. Data show the change in concentration of IL-17A and TGF-β1 (avg+ SE) as a
percentage of the BLM treated group alone from 2-3 independent experiments involving 9-14 mice/group. **; p< 0.005.
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Figure 6 CpG ODN treatment induces the expression of IL-10.
Mice were injected i.p. with 200 μg of control or CpG ODN 5 days
before 0.05 U of BLM was delivery intra-tracheally. Mice were
sacrificed immediately before BLM (day 0 time point) or 3 and
7 days after BLM. IL-10 mRNA expression in the lung was measured
by quantitative RT-PCR. Data represent the mean + SE of combined
results from 2 independent experiments involving 8-10 mice/group/
each time point. **; p< 0.005.
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encoding pro-inflammatory cytokines and chemokines
generally peaking between 3 - 9 hr. This rapid but short
term activity is supported by evidence that intraperito-
neal injection of CpG ODN induces pulmonary inflam-
mation lasting from 1 - 6 hr such that no evidence of
inflammation is detectable at 5 days [29]. Recent studies
indicate that this early pro-inflammatory response is fol-
lowed by a prolonged period of gene suppression
mediated by a counter-regulatory process [24]. Micro-
array studies of spleen cells showed that the signaling cas-
cade triggered by CpG ODN resulted in the up-regulation
of genes including IL-10 whose product suppressed the
initial immune response. This down-regulation occurred
under physiological conditions, was highly reproducible,
and peaked 5 days after CpG administration [24]. Extend-
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Figure 7 Effect of anti-IL-10R Abs on CpG induced protection.
Mice were injected i.p. with 200 μg of CpG ODN 5 days before 0.05
U of BLM or PBS (no BLM) was delivery intra-tracheally. Some groups
were also treated with 200 μg of anti-IL-10R Abs or isotype matched
Abs i.p. on the day of and 5 days after BLM instillation. Results from
5 mice/group are shown.demonstrates that expression of the IL-10 gene in the
lungs is also increased 5 days after CpG administration
(Figure 6). The current work is the first to examine
whether this counter-regulatory process can be harnessed
to prevent the pathological inflammation triggered by a
different agent; in this case, the lung injury induced by
BLM.
Bleomycin is an important chemotherapeutic agent [1-3].
Unfortunately, the lungs are deficient in the enzyme that
detoxifies BLM, and dose-limiting pulmonary toxicity arises
in nearly 20% of patients [7,10-12]. BLM generates DNA-
cleaving free radicals that injure lung cells, leading to the
release factors that attract and stimulate alveolar macro-
phages to produce a variety of cytokines and chemokines,
key among which are IL-1β, IL-6, KC and MIP-2. These
factors recruit and activate additional inflammatory cells,
culminating in the development of pulmonary fibrosis
[13,14].
CpG ODN have historically been used to bolster immune
reactivity in animals with established disease (including
infection, allergy and cancer). In the context of BLM
induced fibrosis, Luckhardt et al. reported that CpG treat-
ment 14 days after intrathecal injection of BLM reduced
lung fibrosis [30]. Although the precise mechanism was not
shown, they suggested that the enhancement of IFN-β
production by CpG ODN might be associated with the re-
duction of fibrosis. IL-12, which is a representative pro-
inflammatory cytokine induced by CpG ODN, was also
reported to inhibit BLM induced lung fibrosis. Keane et al.
reported that 16 consecutive days of IL-12 administration
reduced BLM-induced lung fibrosis and suggested that this
protective effect was mediated via IFN-γ [31]. In all
previous studies, CpG or IL-12 was administered after
BLM and the effect of the resultant Th1 response on lung
fibrosis was monitored. There have been several studies
examing the effect of administering CpG ODN prior to the
development of disease. In an animal model of stroke,
administering CpG ODN 3 days before the onset of brain
ischemia significantly reduced infarct size and this neuro-
protective effect was associated with CpG-induced TNF-α
and type I interferon production [32,33]. In a model of
LPS-induced lung inflammation, CpG ODN administered 1
- 12 hours before LPS inhibited pulmonary injury in an IL-
12 dependent manner [34]. Similarly, CpG ODN delivered
shortly before pathogen challenge elicited an inflammatory
response that improved host resistance to infection [35,36].
Yet the activity of CpG ODN in these systems was uni-
formly dependent on the early induction of a pro-
inflammatory response. The current work is the first to
examine whether the counter-regulatory response peaking
5 days after CpG administration might be harnessed to
therapeutic advantage.
Results show that mice pre-treated with CpG ODN are
resistant to the pulmonary damage induced by BLM
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mice treated with 200 μg of CpG ODN 5 days prior to
BLM instillation (Figure 1). That treatment regime com-
pletely prevented the mortality and significantly reduced
the acute and chronic pulmonary morbidity elicited by
BLM. It also significantly reduced other measures of pul-
monary inflammation, including collagen deposition,
leukocyte accumulation, and the accumulation of IL-1β,
IL-6, KC and MIP-2 in BAL fluid (Figures 2-4). Lowering
the dose of CpG ODN also reduced the protection
achieved, while substituting control ODN resulted in a
complete loss of protection (Figure 1). When administered
only 3 days before BLM (the time at which the counter-
regulatory response first arose), CpG treatment was less
effective, leading to only a 26% improvement in survival
(p< 0.05, data not shown). Delaying the initiation of ther-
apy until the day of or after BLM administration worsened
the inflammatory process (Figure 1C). These outcomes
were not surprising, as CpG ODN have an immediate but
short lasting inflammatory effect on the lungs. We con-
clude that CpG ODN must be administered several days
prior to BLM instillation to harness the counter-
regulatory process and prevent pulmonary inflammation.
Studies were conducted to clarify the mechanism by
which CpG ODN blocked BLM-dependent pulmonary in-
flammation. Previous work showed that the concentration
of IL-17A and TGF-β in BAL rose significantly after the
instillation of BLM (Figure 5 and [16-18]), and that these
factors supported the development of BIP by promoting
the production of pro-inflammatory cytokines and chemo-
kines (including IL-1β, IL-6, KC and MIP-2). Studies using
neutralizing Abs and KO mice showed that the elimin-
ation of IL-17A and/or TGF-β led to a significant reduc-
tion in BLM-induced pulmonary fibrosis [16-18,37].
Other reports showed that IL-10 down-regulated the pro-
duction of both IL-17A and TGF-β [16] and that IL-10
was a key mediator of the counter-regulatory process
responsible for suppressing CpG induced immune activa-
tion [23,25,26].
Consistent with those findings, IL-10 mRNA levels rose
significantly while the levels of IL-17A and TGF-β1 fell
significantly in the BAL of mice pre-treated with CpG
DNA (Figures 5, 6). Control ODN had no such effect,
establishing the specificity of this effect. However when
the activity of IL-10 was blocked with anti-IL-10R Abs, no
reduction in CpG mediated protection was observed
(Figure 7). These findings are consistent with the inter-
pretation that multiple elements of the counter-regulatory
process triggered by CpG ODN contribute to the reduc-
tion in BLM-induced pulmonary inflammation, such that
eliminating a single component (such as IL-10) does not
undermine the protective response.
While failing to identify the precise factors respon-
sible, current results establish the principle that thecounter-regulatory process responsible for suppressing
TLR9-induced gene activation can be harnessed to
block the inflammation arising from an unrelated
stimulus. As pulmonary inflammation represents the
dose-limiting toxicity of many chemotherapeutic agents,
the protective activity of CpG pre-treatment identified
herein may be of widespread utility. In this context,
since chemotherapy schedules are typically established
weeks in advance, the administration of CpG ODN
prior to BLM (or other agents) could be readily incorpo-
rated into these therapeutic protocols.
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